Sabby Management’s Alterity Therapeutics ATHE Stock Holding History

Sabby Management’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-50	Closed	-$838K	–	259
2014 Q1	$838K	Buy	50 +42	+525%	+$23.2K	0.05%	148
2013 Q4	$321K	Buy	+8	New	+$2.39K	0.02%	167

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Sabby Management's ATHE Position: Q1 2021 in Review

Sabby Management sold out of Alterity Therapeutics (ATHE) in Q1 2021, closing a stake of 18,584 shares — an estimated $249K sold.

Sabby Management first reported a position in ATHE in Q1 2014 and held it in 2 quarters. The position peaked at $249K in Q4 2020. 12 funds tracked by Wall St. Rank hold ATHE as of Q1 2021.

Sabby Management reported no remaining Alterity Therapeutics position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 18,584 Alterity Therapeutics shares in Q1 2021, an estimated $249K.
Sabby Management first reported a position in Alterity Therapeutics in Q1 2014 and held it in 2 quarters.
Sabby Management's Alterity Therapeutics position peaked at $249K in Q4 2020.
12 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.